Last reviewed · How we verify
129Xe
Xenon-129 is a hyperpolarized noble gas used as a contrast agent for magnetic resonance imaging to visualize lung ventilation and gas exchange.
Xenon-129 is a hyperpolarized noble gas used as a contrast agent for magnetic resonance imaging to visualize lung ventilation and gas exchange. Used for Pulmonary ventilation and gas exchange imaging in patients with chronic obstructive pulmonary disease, Assessment of regional lung function in asthma and other respiratory disorders.
At a glance
| Generic name | 129Xe |
|---|---|
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Drug class | Hyperpolarized contrast agent |
| Modality | Small molecule |
| Therapeutic area | Pulmonology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
Xenon-129 is polarized to enhance its magnetic resonance signal, allowing it to be inhaled and imaged to assess regional lung ventilation, perfusion, and gas exchange dynamics. This enables non-invasive evaluation of pulmonary function and detection of ventilation defects in various respiratory conditions.
Approved indications
- Pulmonary ventilation imaging in patients with suspected or known lung disease
- Assessment of regional lung function and ventilation defects
Common side effects
Key clinical trials
- Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease (PHASE2)
- 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) (PHASE2)
- Pulmonary Hypertension SOLAR (PHASE2)
- Xenon MRI and Progressive ILD (PHASE2)
- 129 Xenon Imaging in Patients Treated With Sotatercept (PHASE2)
- Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity (PHASE1)
- Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease (PHASE1, PHASE2)
- 129Xe MRI in Pediatric Population With BPD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 129Xe CI brief — competitive landscape report
- 129Xe updates RSS · CI watch RSS
- Children's Hospital Medical Center, Cincinnati portfolio CI